Dose Insider / Analyses / Mounjaro side effects

Mounjaro Side EffectsHow Common Each One Is at 5, 10 and 15 mg, and When They Ease

Updated November 20, 2026 · 18 min read · FDA label 2026, SURPASS 1-5 analysis

The common side effects of Mounjaro are nausea, diarrhea, decreased appetite, vomiting, constipation, indigestion and stomach pain.

18%reported nausea on Mounjaro 15 mg; 12% on 5 mg and 4% on placebo
People reporting nauseaMounjaro label trials, share of participants15 mg18%5 mg12%Placebo4%People reporting nauseaMounjaro label trials, share of participants15 mg18%5 mg12%Placebo4%

Nausea was reported by 18% on 15 mg, 12% on 5 mg and 4% on placebo.

On this page

In the placebo-controlled trials in its label, nausea was reported by 12% of people on 5 mg, 15% on 10 mg and 18% on 15 mg, against 4% on placebo. Most reports of nausea, vomiting and diarrhea came while the dose was being raised and decreased over time, and 3% to 6.6% of people stopped the drug because of stomach or gut reactions.

This page gives the label's number for each effect at each dose, turns the dose steps into dates, sets out the figures for low blood sugar, and shows what the same doses did in the trials of Zepbound, which is the same drug approved for weight. It ends with the warnings and what has been reported since approval.1

How common is each Mounjaro side effect?

The label's main table pools two placebo-controlled trials in adults with type 2 diabetes: one of Mounjaro alone and one of Mounjaro added to basal insulin. Together they cover 718 people on Mounjaro for an average of 36.6 weeks.1

One reaction, each doseFDA label
Reaction

Note each symptom with its date and you will see how your own weeks compare.

Open the app

Two placebo-controlled trials in adults with type 2 diabetes, about 37 weeks. A reaction counts once per person, however mild.

ReactionPlacebo5 mg10 mg15 mg
Nausea4%12%15%18%
Diarrhea9%12%13%17%
Decreased appetite1%5%10%11%
Vomiting2%5%5%9%
Constipation1%6%6%7%
Indigestion3%8%8%5%
Abdominal pain4%6%5%5%
Belching0.4%3%2.5%3.3%
Gas0%1.3%2.5%2.9%
Reflux0.4%1.7%2.5%1.7%
Bloating0.4%0.4%2.9%0.8%
Any stomach or gut reaction20.4%37.1%39.6%43.6%

Mounjaro prescribing information, Table 1 and section 6.1.1

Roughly four in ten people on Mounjaro reported some stomach or gut reaction, about twice the share on placebo. Nausea, diarrhea, vomiting and loss of appetite rise with the dose. Indigestion and stomach pain do not.1

The label says the same held in its larger pool of seven trials, with 5,119 people on Mounjaro for an average of 48.1 weeks: the types and frequency of common reactions were similar to those in the table.1 An analysis of the five main trials, with 6,263 participants, reports ranges across trials: nausea in 12% to 24% of people on the drug, diarrhea in 12% to 22% and vomiting in 2% to 13%, described as transient and mild to moderate.2

Stopping follows the dose more closely than the reactions do. Stomach and gut reactions ended treatment for 3% of people on 5 mg, 5.4% on 10 mg and 6.6% on 15 mg, against 0.4% on placebo. On the top dose that is about one person in fifteen.1

Severe stomach or gut reactions were about as frequent as on placebo: 1.3% on 5 mg, 0.4% on 10 mg and 1.2% on 15 mg, against 0.9%.1

What do the numbers say about each reaction?

Nausea

The most common reaction at every dose, rising by about three points with each step: 12%, 15% and 18%, against 4% on placebo.1 Across the five main trials it ranged up to 24%.2

Diarrhea

Reported by 12% on 5 mg, 13% on 10 mg and 17% on 15 mg. The placebo figure is high here, 9%, so the part attributable to the drug is smaller than for nausea: 3 to 8 points.1

Decreased appetite

Listed as a reaction, although it is also how the drug works: 5% on 5 mg, 10% on 10 mg and 11% on 15 mg reported it, against 1% on placebo.1 The page on what to eat on a GLP-1 covers what goes missing when appetite falls.

Vomiting

Reported by 5% on 5 mg and on 10 mg and 9% on 15 mg, against 2% on placebo.1 Persistent vomiting is the reaction the label ties to dehydration and kidney injury.1

Constipation

Reported by 6% to 7% at every dose, against 1% on placebo, so it does not depend much on the dose.1 Severe constipation, including fecal impaction, is among the reactions reported after approval.1

Indigestion, belching and stomach pain

Indigestion was reported by 8% on 5 mg and 10 mg and 5% on 15 mg, against 3% on placebo, and belching by about 3% against 0.4%. Abdominal pain was close to placebo: 5% to 6% against 4%.1 Pain that is severe or persistent, sometimes spreading to the back, is named in the label as a possible sign of pancreatitis.1

Reading the numbers

Each percentage is the share of people who reported the reaction at least once during a trial of about 37 weeks. It is not the share who felt it at any one moment. The people in these trials were adults with type 2 diabetes, on average 58 years old, with diabetes for 9.1 years; 54% were men.1 The label itself warns that rates from one drug's trials cannot be compared directly with another's.1

When are Mounjaro side effects most likely?

During the step-up. The label states that the majority of reports of nausea, vomiting or diarrhea occurred while the dose was being raised and decreased over time.1 The steps are fixed by the label: 2.5 mg for four weeks, then 5 mg, and after at least four weeks on each dose, increases of 2.5 mg up to 15 mg if more blood sugar control is needed.1

WeeksDoseWhat the label says
1 to 42.5 mgThe starting dose for everyone
5 to 85 mgThe first increase. Most reports of nausea, vomiting and diarrhea come during the step-up weeks
9 to 207.5, 10 and 12.5 mg, if neededEach step after at least four weeks on the dose before
21 onward15 mg, if neededThe highest dose, reached in week 21 at the earliest

Mounjaro prescribing information, sections 2 and 6.1.1

The step-up weeks on my calendarFDA label
The dose I am heading for

    Log each shot and the app keeps these dates for you.

    Open the app

    These are the earliest dates the label allows. Steps above 5 mg are taken only if more blood sugar control is needed, and the prescriber decides each one.

    Someone who stays on 5 mg has one step-up to get through. Someone who goes to 15 mg has five, spread over at least twenty weeks.1 The Mounjaro dosing schedule has the full ladder with the pens and the missed-dose rule.

    Why does Mounjaro upset the stomach?

    The label names one mechanism: Mounjaro delays gastric emptying. It adds a detail that explains the timing: the delay is largest after the first dose and diminishes over time.1

    That is why the label also carries a note about medicines taken by mouth. A slower stomach can change how they are absorbed, and for oral hormonal contraceptives the label advises switching to a non-oral method or adding a barrier method for 4 weeks after starting Mounjaro and after each dose increase.1 The page on tirzepatide and birth control explains the rule.

    How often does Mounjaro cause low blood sugar?

    On its own, almost never. Added to basal insulin or taken with a sulfonylurea, it becomes one of the most frequent reactions in the label.1

    Low blood sugar, by combinationFDA label
    Mounjaro taken

    At least one reading below 54 mg/dL. Alone and with insulin: 40 weeks. With a sulfonylurea: a trial of up to 104 weeks, for which the label gives no placebo figure.

    Blood sugar below 54 mg/dLPlacebo5 mg10 mg15 mg
    Mounjaro alone, 40 weeks1%0%0%0%
    With basal insulin, 40 weeks13%16%19%14%
    With basal insulin: severe0%0%2%1%
    With a sulfonylurea, up to 104 weeks13.8%9.9%12.8%
    With a sulfonylurea: severe0.5%0%0.6%

    Mounjaro prescribing information, Table 2 and section 6.1. Severe means an episode that needed another person's help.1

    The pattern is that the risk comes from the partner medicine. With insulin, the placebo group already had low readings in 13%, and Mounjaro added a few points. The label tells prescribers that the risk may be lowered by reducing the dose of the sulfonylurea or the insulin.1 Eating much less than before, which the drug makes likely, matters more in that situation.

    Does nausea explain the weight loss on Mounjaro?

    No. An analysis of the five main Mounjaro trials split the participants by whether they reported nausea, vomiting or diarrhea. Those who did lost between 6.2 and 14.9 kg, depending on the trial and dose. Those who did not lost between 6.2 and 13.3 kg.2

    With and without stomach reactionsSURPASS 1 to 5
    End of the range across the five trials

    Ranges across five trials and three doses. The smallest and largest values need not come from the same trial.

    The authors concluded that the greater weight reduction with tirzepatide appears to be independent of these reactions.2 A calm stomach on Mounjaro is no sign that the drug is doing less.

    Are the side effects the same on Zepbound?

    The drug and the doses are the same, and the reported rates are higher. Zepbound is tirzepatide approved for weight reduction, and its label comes from 72-week trials in people with obesity or overweight.3

    Same doses, two sets of trialsBoth labels
    Reaction

    Mounjaro: about 37 weeks, adults with type 2 diabetes. Zepbound: 72 weeks, adults with obesity or overweight. Each drug bar belongs with its own placebo.

    ReactionMounjaro trials: placebo, 5, 10, 15 mgZepbound trials: placebo, 5, 10, 15 mg
    Nausea4%, 12%, 15%, 18%8%, 25%, 29%, 28%
    Diarrhea9%, 12%, 13%, 17%8%, 19%, 21%, 23%
    Vomiting2%, 5%, 5%, 9%2%, 8%, 11%, 13%
    Constipation1%, 6%, 6%, 7%5%, 17%, 14%, 11%

    Mounjaro and Zepbound prescribing information.1,3

    The Zepbound trials ran twice as long, which gives each person more time to report a reaction at least once, and they enrolled a different population.1,3 The labels do not say which of these accounts for the gap. The Zepbound side effects timeline covers the weight-loss trials in detail.

    How does Mounjaro compare with Ozempic on side effects?

    One trial tested them against each other. Over 40 weeks in people with type 2 diabetes, three doses of tirzepatide were compared with semaglutide 1 mg, the drug in Ozempic.4

    Reported byTirzepatide, lowest to highest doseSemaglutide 1 mg
    Nausea17% to 22%18%
    Diarrhea13% to 16%12%
    Vomiting6% to 10%8%
    A serious adverse event5% to 7%3%

    SURPASS-2 trial.4

    The two labels, read separately, give a similar picture. Nausea was reported by 12% to 18% across Mounjaro's doses against 4% on placebo, and by 15.8% to 20.3% on Ozempic 0.5 and 1 mg against 6.1% on its placebo.1,6 Those are different trials, which is why the trial that compared the two drugs directly is the better guide.

    At these doses the stomach reactions were about as frequent on the two drugs.4 The pages on Ozempic vs Mounjaro and on Ozempic side effects have the rest.

    Which side effects are outside the stomach and gut?

    The label lists these from its placebo-controlled trials.1

    Hair loss is not in Mounjaro's trial tables. It is on the list of reactions reported after approval.1 In the Zepbound trials it was reported by 4% to 5% against 1% on placebo, and the page on hair loss explains its link with weight loss.3

    What are the serious side effects, and how often do they happen?

    The warnings section of the label covers them. Where the trials produced a count, it is given here.1

    WarningWhat the label reports
    Thyroid C-cell tumorsA boxed warning at the top of the label
    PancreatitisConfirmed in 13 people on Mounjaro, 0.23 per 100 years of exposure, and 3 on comparison treatments, 0.11 per 100 years
    Low blood sugarWith insulin or a sulfonylurea; the figures are in the section above
    Allergic reactionsAnaphylaxis and angioedema have been reported
    Kidney injuryFrom dehydration caused by nausea, vomiting or diarrhea
    Severe stomach and gut reactions1.3%, 0.4% and 1.2% on 5, 10 and 15 mg, against 0.9% on placebo. Not recommended in severe gastroparesis
    Diabetic eye diseaseRapid improvement in blood sugar has been associated with a temporary worsening of retinopathy. People with a history of it should be monitored
    Gallbladder diseaseGallstones, biliary colic or gallbladder removal in 0.6% on Mounjaro and nobody on placebo
    Aspiration during anesthesiaReported with GLP-1 drugs during procedures under general anesthesia or deep sedation

    Mounjaro prescribing information, sections 5 and 6.1

    On the eyes the label is candid about a gap: Mounjaro has not been studied in people with the more advanced forms of diabetic retinopathy or with diabetic macular edema.1

    What the label tells doctors and patients to do

    Pancreatitis. Watch for persistent or severe abdominal pain, sometimes radiating to the back, with or without nausea or vomiting.1

    Thyroid. Patients are to be told about the symptoms of a thyroid tumor: a lump in the neck, trouble swallowing, shortness of breath or hoarseness that does not go away.1

    Kidneys. The label describes reports, after approval, of acute kidney injury in people on GLP-1 drugs or Mounjaro, in some cases requiring hemodialysis. Most occurred in people whose nausea, vomiting or diarrhea had led to dehydration.1

    Gallbladder. If gallstones are suspected, the label calls for gallbladder studies and follow-up.1

    Eyes. Patients are told to contact their healthcare provider about changes in vision during treatment.1

    What has been reported since approval?

    The label lists reactions reported after tirzepatide came into wide use: anaphylaxis and angioedema; pancreatitis, including fatal cases; ileus, intestinal obstruction and severe constipation including fecal impaction; aspiration during procedures; kidney failure, sometimes requiring hemodialysis; and hair loss. It cautions that such reports are voluntary and come from a population of unknown size, so their frequency cannot be reliably estimated and a causal link cannot always be established.1

    Do side effects differ with age or kidney disease?

    Older adults. In the label's pool of seven trials, 30.1% of the people on Mounjaro were 65 or older and 4.1% were 75 or older. The label detected no general difference in safety between them and younger patients, and adds that greater sensitivity of some older individuals cannot be ruled out.1

    Kidney disease. No dose adjustment is recommended for reduced kidney function, including end-stage kidney disease.1 The warning about dehydration matters more here, because fluid lost to vomiting or diarrhea is what the label links to kidney injury.

    Who was in these trials?

    Adults with type 2 diabetes for an average of 9.1 years, with a mean age of 58 and an HbA1c of 8.1%. At the start 13% had retinopathy on eye examination, and kidney function was normal in 53% and mildly reduced in 39%.1 People using Mounjaro without diabetes are outside this description, and for them the Zepbound trials are the closer match.

    Are the side effects different in children and teenagers?

    Mostly the same, with three exceptions. In the trial of 97 patients aged 10 and older with type 2 diabetes, the label says reactions on 5 mg and 10 mg were consistent with those in adults except for more vomiting, more abdominal pain and more low blood sugar. Vomiting was reported by 16% on 5 mg and 12% on 10 mg, against 3% on placebo, and abdominal pain by 22% and 15%, against 9%. No episode of low blood sugar was severe.1

    Do side effects stop when you stop Mounjaro?

    Over a few weeks. The label gives tirzepatide a half-life of about 5 days, so the level falls by half roughly every five days after the last dose.1 By that arithmetic about 3% of the last dose remains after five half-lives, which is 25 days. The page on how long tirzepatide stays in your system shows the curve day by day.

    What helps while they last?

    The slow ladder is the label's own answer: everyone starts on 2.5 mg for four weeks, and each increase waits at least four weeks. The label describes 2.5 mg as a dose for starting treatment that is not intended for blood sugar control, which is to say it exists to let the body adjust.1 Whether to take the next step is the prescriber's decision.

    For food, a 2025 advisory from four medical societies suggests smaller, more frequent meals and less fat and fiber for the first few days after a dose change, a small breakfast followed by small meals every 3 to 4 hours, and steady fluids. For constipation it recommends fluids and fiber from foods, raised gradually, and it notes that alcohol may worsen nausea and reflux.5 The page on what to eat on a GLP-1 has the details, with a menu for a queasy day.

    When should you call the prescriber?

    The label's warnings point to these situations.1

    Short answers to common questions

    What is the most common side effect of Mounjaro?

    Nausea: 12% on 5 mg, 15% on 10 mg and 18% on 15 mg, against 4% on placebo.

    When do Mounjaro side effects start, and do they go away?

    The label says most reports of nausea, vomiting and diarrhea came during dose escalation and decreased over time.

    Are side effects worse on 15 mg than on 5 mg?

    Nausea, diarrhea, vomiting and loss of appetite are more frequent: 18%, 17%, 9% and 11% on 15 mg against 12%, 12%, 5% and 5% on 5 mg. Constipation and stomach pain hardly change.

    How many people stop Mounjaro because of side effects?

    Because of stomach or gut reactions, 3% on 5 mg, 5.4% on 10 mg and 6.6% on 15 mg, against 0.4% on placebo.

    Does Mounjaro cause low blood sugar?

    Not on its own in the label trial: no one on Mounjaro alone had a reading below 54 mg/dL. With basal insulin, 14% to 19% did, against 13% on placebo with insulin.

    Does Mounjaro cause diarrhea or constipation more often?

    Diarrhea: 12% to 17% depending on the dose, against 6% to 7% for constipation.

    Does Mounjaro cause hair loss?

    Hair loss is not in Mounjaro's trial tables. It is among the reactions reported after approval, without a frequency.

    Does Mounjaro cause pancreatitis?

    It was confirmed in 13 people on Mounjaro in the trials, 0.23 per 100 years of exposure, against 0.11 on comparison treatments.

    Does Mounjaro raise heart rate?

    By an average of 2 to 4 beats a minute, against 1 beat on placebo.

    Can Mounjaro cause gastroparesis?

    The label says Mounjaro delays stomach emptying, most after the first dose, and is not recommended for people with severe gastroparesis. Ileus and intestinal obstruction are among the reactions reported after approval, without a frequency.

    Is Mounjaro or Ozempic easier on the stomach?

    In the trial that compared them, nausea was reported by 17% to 22% on tirzepatide, depending on the dose, and by 18% on semaglutide 1 mg.

    Why are Zepbound's numbers higher if the drug is the same?

    The Zepbound trials ran 72 weeks in people with obesity or overweight, against about 37 weeks in people with type 2 diabetes for Mounjaro. The labels do not say how much each difference contributes.

    Does having no nausea mean Mounjaro is not working?

    No. In five trials, people without nausea, vomiting or diarrhea lost 6.2 to 13.3 kg, against 6.2 to 14.9 kg for those who had them.

    How long do Mounjaro side effects last?

    The label gives no day counts. It says reports of nausea, vomiting and diarrhea decreased over time, and the analysis of the five main trials describes them as transient. The Zepbound timeline page has the measured lengths from the weight-loss trials.

    Do side effects come back with each dose increase?

    They can. The label says most reports of nausea, vomiting and diarrhea came during dose escalation, and a move to 15 mg involves five increases.

    Does Mounjaro cause dizziness?

    Dizziness is not in Mounjaro's table. In the Zepbound trials of the same drug it was reported by 4% to 5%, against 2% on placebo.

    Does Mounjaro cause burping?

    Belching was reported by about 3% of people on Mounjaro, against 0.4% on placebo.

    Does Mounjaro cause fatigue?

    Fatigue is not in Mounjaro's table. In the Zepbound trials of the same drug it was reported by 5% to 7%, against 3% on placebo.

    Are injection site reactions common?

    They were reported by 3.2% on Mounjaro and 0.4% on placebo, and more often in people who developed antibodies to the drug.

    Does Mounjaro affect birth control pills?

    The label advises people on oral hormonal contraceptives to switch to a non-oral method or add a barrier method for 4 weeks after starting and after each dose increase, because the drug delays stomach emptying.

    Does Mounjaro affect the eyes?

    The label notes that rapid improvement in blood sugar has been associated with a temporary worsening of diabetic retinopathy, and says people with a history of it should be monitored.

    Are side effects worse in older people?

    The label found no general difference in safety between people 65 and older and younger people, and says greater sensitivity in some older individuals cannot be ruled out.

    How the calculators work

    The reaction chart shows Table 1 of the Mounjaro label and the figures in the text around it. The calendar places the label's dose steps at 4-week intervals from the date you enter, up to the dose you choose. The low blood sugar chart shows Table 2 of the label and the sulfonylurea figures beside it.

    The weight chart shows the two ranges reported by the analysis of the five main Mounjaro trials. The comparison chart sets Table 1 of the Mounjaro label next to the adverse reaction table of the Zepbound label, each with its own placebo group.

    The label's trials ran for about 37 to 48 weeks in people with type 2 diabetes. Neither the label nor the analysis says what an individual should expect.

    Sources

    1. MOUNJARO (tirzepatide) prescribing information, NDA 215866/S-052, revised April 2026. U.S. Food and Drug Administration; sections 2, 5, 6, 7 and 12. accessdata.fda.gov
    2. Patel H, Khunti K, Rodbard HW, Bajaj HS, Bray R, Kindracki Z, Rodríguez Á. Gastrointestinal adverse events and weight reduction in people with type 2 diabetes treated with tirzepatide in the SURPASS clinical trials. Diabetes Obes Metab 2024;26:473-481. doi:10.1111/dom.15333
    3. ZEPBOUND (tirzepatide) prescribing information, NDA 217806/S-041, revised August 2026. U.S. Food and Drug Administration; sections 6.1 and 14. accessdata.fda.gov
    4. Frías JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med 2021;385:503-515. doi:10.1056/NEJMoa2107519
    5. Mozaffarian D, Agarwal M, Aggarwal M, et al. Nutritional priorities to support GLP-1 therapy for obesity: a joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. Obesity (Silver Spring) 2025;33:1475-1503. doi:10.1002/oby.24336
    6. OZEMPIC (semaglutide) injection prescribing information, NDA 209637/S-039, revised May 2026. U.S. Food and Drug Administration; section 6.1. accessdata.fda.gov

    Related analyses

    Log each dose and each symptom, and see your own timeline.

    Open Dose Insider